<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erythrasma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erythrasma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Erythrasma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cheryl A Armstrong, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Erythrasma is a superficial infection of the skin caused by <em>Corynebacterium minutissimum</em>, a gram-positive, non-spore-forming bacillus (<a class="graphic graphic_picture graphicRef99902" href="/z/d/graphic/99902.html" rel="external">picture 1</a>). The disorder typically presents as macerated, scaly plaques between the toes or erythematous to brown patches or thin plaques in intertriginous areas (<a class="graphic graphic_picture graphicRef99903 graphicRef71848 graphicRef51713 graphicRef80242 graphicRef59529 graphicRef99904 graphicRef99905" href="/z/d/graphic/99903.html" rel="external">picture 2A-G</a>).</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of erythrasma will be discussed here.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Erythrasma is a common disorder. However, the prevalence is difficult to assess since many patients do not seek treatment or have subclinical infection. In a 1970 study of 754 college students in the United Kingdom, 19 percent had erythrasma [<a href="#rid1">1</a>]. A subsequent study of patients seen in a New Zealand dermatology clinic found a prevalence of 20 percent [<a href="#rid2">2</a>]. Higher prevalences have been reported in soldiers and institutionalized patients [<a href="#rid3">3,4</a>].</p><p>Erythrasma often occurs in healthy adults [<a href="#rid1">1</a>], but diabetic patients, older adults, or immunocompromised patients have increased risk for the disorder [<a href="#rid5">5</a>]. Conditions predisposing to skin occlusion and moisture also contribute to erythrasma, including obesity, hyperhidrosis, and living in tropical climates. There are reports of erythrasma in patients with active hidradenitis suppurativa [<a href="#rid6">6</a>]. Erythrasma is rare in children [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Erythrasma is caused by <em>C. minutissimum</em>, a component of the normal skin flora. <em>C. minutissimum</em> is a gram-positive, non-spore-forming, aerobic or facultative bacillus [<a href="#rid8">8</a>]. Under conditions of moisture and occlusion, <em>C. minutissimum</em> proliferates in the upper levels of the stratum corneum.</p><p>Corynebacteria may also cause trichomycosis axillaris (<a class="graphic graphic_picture graphicRef64304" href="/z/d/graphic/64304.html" rel="external">picture 3</a>) and pitted keratolysis (<a class="graphic graphic_picture graphicRef81393" href="/z/d/graphic/81393.html" rel="external">picture 4</a>) [<a href="#rid7">7</a>]. The coexistence of erythrasma, pitted keratolysis, and trichomycosis axillaris has been documented [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Erythrasma most commonly involves the toe webs, followed by the groin and axilla. In one study of college students, 85, 16, and 10 percent of students had interdigital, groin, or axillary disease, respectively [<a href="#rid1">1</a>]. Another study involving institutionalized patients showed a similar trend; 70 percent of patients with erythrasma had<strong> </strong>pedal interdigital disease, 42 percent had groin disease, and 36 percent had axillary disease [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Interdigital</span><span class="headingEndMark"> — </span>Erythrasma is the most common cause of interdigital bacterial infection on the feet. This variant exhibits scaling and maceration of the web spaces (<a class="graphic graphic_picture graphicRef99903 graphicRef71848" href="/z/d/graphic/99903.html" rel="external">picture 2A-B</a>), usually between the fourth and fifth toes. Interdigital erythrasma may be asymptomatic or pruritic. Interdigital erythrasma may occur concomitantly with dermatophyte or candidal infection [<a href="#rid2">2,10</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Intertriginous</span><span class="headingEndMark"> — </span>Intertriginous erythrasma exhibits well-defined, erythematous patches or thin plaques in the axillae, inframammary region, umbilicus, or groin (<a class="graphic graphic_picture graphicRef51713 graphicRef80242 graphicRef59529 graphicRef99904 graphicRef99905" href="/z/d/graphic/51713.html" rel="external">picture 2C-G</a>). With time, the initial reddened color changes to brown. Involved areas often have visible fine scale and wrinkling that gives the skin a "cigarette paper" appearance. Affected areas are asymptomatic or mildly pruritic.</p><p class="headingAnchor" id="H7"><span class="h2">Disciform</span><span class="headingEndMark"> — </span>A rare disciform variant of erythrasma consists of generalized, round plaques not confined to intertriginous areas (<a class="graphic graphic_picture graphicRef85723" href="/z/d/graphic/85723.html" rel="external">picture 5</a>) [<a href="#rid11">11</a>]. Disciform erythrasma has been reported to occur more frequently in Black women who live in tropical climates [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Genital/perianal</span><span class="headingEndMark"> — </span>Erythrasma is an occasional cause of chronic pruritus ani [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/2549.html" rel="external">"Approach to the patient with anal pruritus"</a>.)</p><p>Rarely, erythrasma may affect the vulva, causing chronic pruritus that may mimic candidal infection [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of erythrasma is based upon physical appearance and the presence of coral-red fluorescence with a Wood's lamp. A Gram stain, culture, or biopsy can confirm the diagnosis, but usually is not necessary.</p><p>If a Wood's lamp examination or other confirmatory tests are not feasible but there is a high clinical suspicion for<em> </em>erythrasma, it is reasonable to initiate empiric treatment with a topical agent. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H25468000"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Interdigital scaling and maceration should raise suspicion for interdigital erythrasma, and well-defined erythematous or brown patches or thin plaques in intertriginous areas should raise suspicion for the intertriginous variant.</p><p>A Wood's lamp examination depicting coral-red fluorescence confirms the diagnosis of erythrasma (<a class="graphic graphic_picture graphicRef62143" href="/z/d/graphic/62143.html" rel="external">picture 6</a>). This fluorescence is due to the production of porphyrins by <em>C. minutissimum</em>. A false negative test may occur if the patient has bathed soon before the examination, since porphyrins are water-soluble and can be washed away [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Wood's lamp examination (black light)'</a>.)</p><p class="headingAnchor" id="H192301814"><span class="h2">Gram stain</span><span class="headingEndMark"> — </span>Gram stain of a skin scraping will reveal gram-positive filaments and rods, consistent with detection of <em>C. minutissimum </em>(<a class="graphic graphic_picture graphicRef99902" href="/z/d/graphic/99902.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H192300990"><span class="h2">KOH preparation</span><span class="headingEndMark"> — </span>For patients with interdigital involvement, a potassium hydroxide (KOH) preparation of a skin scraping is suggested to assess for concomitant dermatophyte infection [<a href="#rid10">10,15</a>]. (See <a class="local">'Interdigital'</a> above and  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p class="headingAnchor" id="H192300979"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Although rarely indicated, the bacterium can be cultured on media containing 20% fetal bovine serum, 2% agar, and 78% tissue culture medium 199 [<a href="#rid16">16</a>].</p><p><em>C. minutissimum</em> can also be seen on skin biopsy (<a class="graphic graphic_picture graphicRef71545" href="/z/d/graphic/71545.html" rel="external">picture 7</a>). The organism is difficult to detect on hematoxylin- and eosin-stained slides; visualization may be enhanced by use of special stains such as periodic acid-Schiff and Giemsa.</p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Other dermatologic diagnoses have clinical features similar to erythrasma, for example:</p><p class="bulletIndent1"><span class="glyph">●</span>Seborrheic dermatitis (<a class="graphic graphic_picture graphicRef53407" href="/z/d/graphic/53407.html" rel="external">picture 8</a>) (see  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inverse psoriasis (<a class="graphic graphic_picture graphicRef78531" href="/z/d/graphic/78531.html" rel="external">picture 9</a>) (see  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Inverse (intertriginous) psoriasis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Candidiasis (<a class="graphic graphic_picture graphicRef99894" href="/z/d/graphic/99894.html" rel="external">picture 10</a>) (see  <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">"Intertrigo"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dermatophytosis (<a class="graphic graphic_picture graphicRef71067" href="/z/d/graphic/71067.html" rel="external">picture 11</a>) (see  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tinea versicolor (pityriasis versicolor) (<a class="graphic graphic_picture graphicRef59533" href="/z/d/graphic/59533.html" rel="external">picture 12</a>) (see  <a class="medical medical_review" href="/z/d/html/4039.html" rel="external">"Tinea versicolor (pityriasis versicolor)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parapsoriasis (may resemble disciform variant) (<a class="graphic graphic_picture graphicRef68028" href="/z/d/graphic/68028.html" rel="external">picture 13</a>) (see  <a class="medical medical_review" href="/z/d/html/15284.html" rel="external">"Parapsoriasis (small plaque and large plaque parapsoriasis)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pityriasis rotunda (may resemble disciform variant)</p><p></p><p>Seborrheic dermatitis and inverse psoriasis can mimic intertriginous erythrasma. Seborrheic dermatitis is suggested by the presence of erythema and greasy scale on the scalp, eyebrows, or nasolabial folds. Inverse psoriasis plaques tend to have a shinier appearance compared with erythrasma and may be accompanied by other manifestations of psoriasis. The characteristic coral-red fluorescence with Wood's lamp examination distinguishes erythrasma from these disorders.</p><p>Interdigital tinea pedis can be clinically indistinguishable from interdigital erythrasma [<a href="#rid10">10</a>]. A potassium hydroxide (KOH) preparation helps to identify dermatophytosis, tinea versicolor, and candidiasis. Although dermatophyte or candidal infections may coexist with erythrasma, a positive KOH preparation in the absence of coral-red fluorescence suggests an isolated fungal infection. Tinea cruris often exhibits an active scaling border, a clinical feature uncommon in erythrasma. (See  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p>Small plaque parapsoriasis and large plaque parapsoriasis are characterized by chronic, asymptomatic or mildly pruritic erythematous plaques that typically occur on the trunk and proximal extremities. (See  <a class="medical medical_review" href="/z/d/html/15284.html" rel="external">"Parapsoriasis (small plaque and large plaque parapsoriasis)"</a>.)</p><p>Pityriasis rotunda is a rare disorder of keratinization characterized by multiple 2 to 10 cm, round to oval, hyperpigmented or hypopigmented plaques on the trunk or extremities [<a href="#rid17">17</a>]. Parapsoriasis and pityriasis rotunda may be differentiated from each other and from erythrasma by skin biopsy.</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Erythrasma responds to a variety of topical and oral therapies, although recurrence is common. Evidence supporting or comparing various treatments is limited. Treatment selection depends on the extent of disease and drug cost or availability. We recommend treatment with topical therapy for patients with limited skin involvement and suggest systemic therapy for patients with widespread disease.</p><p class="headingAnchor" id="H192301927"><span class="h2">Localized erythrasma</span><span class="headingEndMark"> — </span>For patients with localized disease, topical therapy with antibacterial agents such as <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> is usually effective. Our first-line treatment is typically topical clindamycin or erythromycin; fusidic acid is not available in the United States. Limited data suggest that topical imidazole antifungal drugs also have activity against gram-positive bacteria, including <em>C. minutissimum</em>, and may effectively treat erythrasma [<a href="#rid5">5,18</a>]. Topical therapies are generally applied twice daily for two to three weeks.</p><p class="headingAnchor" id="H192301266"><span class="h3">Topical clindamycin or erythromycin</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> have been used for erythrasma for many years. Clinical experience supports the efficacy of these therapies [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1191557439"><span class="h3">Topical fusidic acid</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a> was highly effective when applied twice daily for up to two weeks in randomized trials and a small observational study [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H25467923"><span class="h3">Topical imidazole antifungal agents</span><span class="headingEndMark"> — </span>In randomized trials of topical antifungal therapies that included small numbers of patients with erythrasma, treatment with <a class="drug drug_general" data-topicid="9727" href="/z/d/drug information/9727.html" rel="external">oxiconazole</a>, <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a>, <a class="drug drug_general" data-topicid="9998" href="/z/d/drug information/9998.html" rel="external">tioconazole</a>, or <a class="drug drug_general" data-topicid="9400" href="/z/d/drug information/9400.html" rel="external">econazole</a> twice daily for 7 to 60 days cleared more than 90 percent of erythrasma [<a href="#rid18">18,22,23</a>]. Once-daily treatment with oxiconazole was also efficacious [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H192301466"><span class="h3">Other topical therapies</span><span class="headingEndMark"> — </span>Other topical therapies (<a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> 2% ointment [<a href="#rid24">24</a>], Whitfield's ointment [<a href="#rid5">5</a>], topical <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a>, and special antibacterial soaps [<a href="#rid5">5</a>]) have been reported as successful treatments, though efficacy data are limited. Given the high efficacy and tolerability of topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> and topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, we do not typically treat with these agents. In particular, Whitfield's ointment may cause significant irritation on intertriginous skin, and the efficacy of benzoyl peroxide and commercially available antibacterial soaps is unclear.</p><p class="headingAnchor" id="H14"><span class="h2">Extensive erythrasma</span><span class="headingEndMark"> — </span>It can be difficult to treat large body areas with topical therapies. Extensive disease may warrant oral therapy. We suggest <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> (single 1 g dose for adults) or oral <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> (1 g per day [in divided doses] for 14 days for adults).</p><p class="headingAnchor" id="H25467929"><span class="h3">Clarithromycin or oral erythromycin</span><span class="headingEndMark"> — </span>In a placebo-controlled randomized trial that assessed the efficacy of <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> (1 g per day for 14 days), a single 1 g dose of <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, and topical 2% <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a> (applied twice daily for 14 days) in adults with erythrasma, all treatments reduced Wood's light reflection scores compared with placebo [<a href="#rid21">21</a>]. Fusidic acid had the lowest reflection scores at day 14, and a significant difference in scores between patients treated with erythromycin and clarithromycin was not detected. A complete response (reflection score of 0) with the fusidic acid, clarithromycin, erythromycin, placebo cream, and placebo tablet groups were 97, 67, 53, 13, and 3 percent, respectively. Successful treatment with erythromycin or a single 1 g oral dose of clarithromycin has also been documented in case reports [<a href="#rid13">13,25,26</a>].</p><p>Oral <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> is usually given at a dose of 250 mg four times per day for 14 days for adults [<a href="#rid5">5</a>]. Gastrointestinal distress (nausea, diarrhea, abdominal pain) is a common side effect of therapy. Enteric-coated erythromycin (333 mg three times daily) may offset gastrointestinal side effects. Antibiotic resistance may occur in some patients who fail to respond to erythromycin, as reported in a study of 40 patients [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H25467935"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> (250 mg four times per day for 14 days) has been used to treat erythrasma, although it may be less beneficial than <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> for intertriginous disease [<a href="#rid5">5</a>].</p><p>Photodynamic therapy (PDT) has been reported to improve erythrasma [<a href="#rid28">28</a>], but is not a recommended treatment. This technique takes advantage of the natural porphyrins produced by <em>C. minutissimum</em>. In a study that evaluated the effect of a red light-emitting PDT device in 13 patients with erythrasma, patients were reported to have a reduction in size of their erythrasma lesions, but less than 25 percent of the treated patients had complete clearance [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H650557318"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Failure to respond to appropriate therapy may suggest that the diagnosis of erythrasma is not correct or that there is a concomitant underlying disease process. In these cases, referral to a dermatologist may be helpful.</p><p class="headingAnchor" id="H16"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Affected patients should be examined for disease at other sites. Persistent disease in untreated sites may contribute to disease recurrence [<a href="#rid5">5</a>].</p><p>Occlusion and moisture contribute to the development of erythrasma; therefore, measures to minimize skin occlusion and moisture may help to prevent infection. Control of hyperhidrosis with aluminum chloride prevented the recurrence in one observational study [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">Benzoyl peroxide</a> or antibacterial soaps may be preventive treatments [<a href="#rid29">29</a>], but confirmatory data are lacking.</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – Erythrasma is a superficial infection caused by <em>Corynebacterium minutissimum</em>. The disorder occurs in healthy adults, but individuals with diabetes mellitus or immunodeficiency may be at increased risk. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Interdigital disease is the most common presentation of erythrasma, characterized by scaly, macerated skin in the toe web spaces (<a class="graphic graphic_picture graphicRef99903 graphicRef71848" href="/z/d/graphic/99903.html" rel="external">picture 2A-B</a>). Coinfection with dermatophytes or <em>Candida</em> may occur. Erythematous to brown patches or plaques in the axillae, inframammary areas, umbilicus, or groin characterize the intertriginous variant (<a class="graphic graphic_picture graphicRef51713 graphicRef80242 graphicRef59529 graphicRef99904 graphicRef99905" href="/z/d/graphic/51713.html" rel="external">picture 2C-G</a>). Erythrasma is usually asymptomatic or mildly pruritic. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The skin findings plus examination with a Wood's lamp revealing coral-red fluorescence confirms the diagnosis (<a class="graphic graphic_picture graphicRef62143" href="/z/d/graphic/62143.html" rel="external">picture 6</a>). For patients with interdigital involvement, microscopic examination of a skin scraping with a potassium hydroxide (KOH) preparation helps to determine whether there is concomitant dermatophyte infection. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Localized erythrasma</strong> – For patients with localized erythrasma, we recommend treatment with topical therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, and topical <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a> are commonly used treatments. All are usually applied twice daily for 14 days. Topical fusidic acid is not available in the United States. (See <a class="local">'Localized erythrasma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive erythrasma</strong> – For patients with more extensive involvement, we suggest treatment with oral <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> or oral <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Extensive erythrasma'</a> above.)</p><p></p><p class="headingAnchor" id="H886129"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mariah Brown, MD, and Sylvia Brice, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Somerville DA. Erythrasma in normal young adults. J Med Microbiol 1970; 3:57.</a></li><li><a class="nounderline abstract_t">Allen S, Christmas TI, McKinney W, et al. The Auckland skin clinic tinea pedis and erythrasma study. N Z Med J 1990; 103:391.</a></li><li><a class="nounderline abstract_t">Somerville DA, Seville RH, Cunningham RC, et al. Erythrasma in a hospital for the mentally subnormal. Br J Dermatol 1970; 82:355.</a></li><li><a class="nounderline abstract_t">Svejgaard E, Christophersen J, Jelsdorf HM. Tinea pedis and erythrasma in Danish recruits. Clinical signs, prevalence, incidence, and correlation to atopy. J Am Acad Dermatol 1986; 14:993.</a></li><li><a class="nounderline abstract_t">Holdiness MR. Management of cutaneous erythrasma. Drugs 2002; 62:1131.</a></li><li><a class="nounderline abstract_t">Gruenstein D, Levitt JO. Erythrasma in 4 skin of color patients with hidradenitis suppurativa. JAAD Case Rep 2021; 13:127.</a></li><li><a class="nounderline abstract_t">Blaise G, Nikkels AF, Hermanns-Lê T, et al. Corynebacterium-associated skin infections. Int J Dermatol 2008; 47:884.</a></li><li><a class="nounderline abstract_t">Penton PK, Tyagi E, Humrighouse BW, McQuiston JR. Complete Genome Sequence of Corynebacterium minutissimum, an Opportunistic Pathogen and the Causative Agent of Erythrasma. Genome Announc 2015; 3.</a></li><li><a class="nounderline abstract_t">Rho NK, Kim BJ. A corynebacterial triad: Prevalence of erythrasma and trichomycosis axillaris in soldiers with pitted keratolysis. J Am Acad Dermatol 2008; 58:S57.</a></li><li><a class="nounderline abstract_t">Inci M, Serarslan G, Ozer B, et al. The prevalence of interdigital erythrasma in southern region of Turkey. J Eur Acad Dermatol Venereol 2012; 26:1372.</a></li><li><a class="nounderline abstract_t">Engber PB, Mandel EH. Generalized disciform erythrasma. Int J Dermatol 1979; 18:633.</a></li><li><a class="nounderline abstract_t">Bowyer A, McColl I. Erythrasma and pruritus ani. Acta Derm Venereol 1971; 51:444.</a></li><li><a class="nounderline abstract_t">Mattox TF, Rutgers J, Yoshimori RN, Bhatia NN. Nonfluorescent erythrasma of the vulva. Obstet Gynecol 1993; 81:862.</a></li><li><a class="nounderline abstract_t">Wilson BB, Wagenseller A, Noland MM. An atypical presentation of erythrasma. J Am Acad Dermatol 2012; 67:e217.</a></li><li><a class="nounderline abstract_t">Sariguzel FM, Koc AN, Yagmur G, Berk E. Interdigital foot infections: Corynebacterium minutissimum and agents of superficial mycoses. Braz J Microbiol 2014; 45:781.</a></li><li><a class="nounderline abstract_t">Sindhuphak W, MacDonald E, Smith EB. Erythrasma. Overlooked or misdiagnosed? Int J Dermatol 1985; 24:95.</a></li><li><a class="nounderline abstract_t">Mirsky L, Watters K, Jafarian F. Chronic hyperpigmented scaly plaques. Pityriasis rotunda (PR). Arch Dermatol 2012; 148:1073.</a></li><li><a class="nounderline abstract_t">Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987; 175:293.</a></li><li><a class="nounderline abstract_t">Cochran RJ, Rosen T, Landers T. Topical treatment for erythrasma. Int J Dermatol 1981; 20:562.</a></li><li><a class="nounderline abstract_t">Hamann K, Thorn P. Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice. Scand J Prim Health Care 1991; 9:35.</a></li><li><a class="nounderline abstract_t">Avci O, Tanyildizi T, Kusku E. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat 2013; 24:70.</a></li><li><a class="nounderline abstract_t">Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983; 166 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">Clayton YM, Hay RJ, McGibbon DH, Pye RJ. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7:543.</a></li><li><a class="nounderline abstract_t">Greywal T, Cohen PR. Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Wharton JR, Wilson PL, Kincannon JM. Erythrasma treated with single-dose clarithromycin. Arch Dermatol 1998; 134:671.</a></li><li><a class="nounderline abstract_t">Chodkiewicz HM, Cohen PR. Erythrasma: successful treatment after single-dose clarithromycin. Int J Dermatol 2013; 52:516.</a></li><li><a class="nounderline abstract_t">Turk BG, Turkmen M, Aytimur D. Antibiotic susceptibility of Corynebacterium minutissimum isolated from lesions of Turkish patients with erythrasma. J Am Acad Dermatol 2011; 65:1230.</a></li><li><a class="nounderline abstract_t">Darras-Vercambre S, Carpentier O, Vincent P, et al. Photodynamic action of red light for treatment of erythrasma: preliminary results. Photodermatol Photoimmunol Photomed 2006; 22:153.</a></li><li class="breakAll">Halpern AV, Heymann WR. Bacterial diseases. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier, 2008. p.1075.</li></ol></div><div id="topicVersionRevision">Topic 4031 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5448882" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Erythrasma in normal young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385417" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Auckland skin clinic tinea pedis and erythrasma study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4245564" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Erythrasma in a hospital for the mentally subnormal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3722494" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tinea pedis and erythrasma in Danish recruits. Clinical signs, prevalence, incidence, and correlation to atopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010076" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of cutaneous erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195323" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Erythrasma in 4 skin of color patients with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937649" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Corynebacterium-associated skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792058" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Complete Genome Sequence of Corynebacterium minutissimum, an Opportunistic Pathogen and the Causative Agent of Erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191714" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A corynebacterial triad: Prevalence of erythrasma and trichomycosis axillaris in soldiers with pitted keratolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21977942" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The prevalence of interdigital erythrasma in southern region of Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/511426" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Generalized disciform erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4109425" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erythrasma and pruritus ani.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469500" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonfluorescent erythrasma of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062922" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An atypical presentation of erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25477907" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Interdigital foot infections: Corynebacterium minutissimum and agents of superficial mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3988422" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Erythrasma. Overlooked or misdiagnosed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986863" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic hyperpigmented scaly plaques. Pityriasis rotunda (PR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3319722" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : One daily application of oxiconazole cream is sufficient for treating dermatomycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7309310" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Topical treatment for erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2041927" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923567" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6350072" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6756715" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28537862" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645634" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Erythrasma treated with single-dose clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23046434" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Erythrasma: successful treatment after single-dose clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082845" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antibiotic susceptibility of Corynebacterium minutissimum isolated from lesions of Turkish patients with erythrasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16719870" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Photodynamic action of red light for treatment of erythrasma: preliminary results.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
